Do minoxidil and finasteride cause erectile dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Minoxidil and Finasteride Cause Erectile Dysfunction?

Finasteride does cause erectile dysfunction in a subset of men (2-4% absolute increase over placebo), while minoxidil does not cause ED. The sexual side effects of finasteride are well-documented in FDA labeling and clinical guidelines, whereas minoxidil—whether topical or oral—has no established association with erectile dysfunction 1, 2.

Finasteride and Erectile Dysfunction

Established Risk from FDA Labeling and Guidelines

Finasteride consistently demonstrates sexual adverse effects across multiple large-scale trials:

  • Erectile dysfunction occurs in 8.1% of finasteride users vs 3.7% on placebo in Year 1 (absolute increase of 4.4%), though this decreases to 5.1% in both groups by Years 2-4 1
  • Additional sexual side effects include: decreased libido (6.4% vs 3.4%), decreased ejaculate volume (3.7% vs 0.8%), and ejaculation disorders 3
  • The FDA label explicitly warns that sexual dysfunction can persist after discontinuation in some patients, including ED, decreased libido, and ejaculation disorders 1

Mechanism and Clinical Context

The sexual dysfunction stems from finasteride's mechanism as a 5-alpha reductase inhibitor, which reduces dihydrotestosterone (DHT) levels and interferes with androgenic pathways 4. Guidelines note these effects are "reversible and therefore uncommon after the first year of therapy" for most patients 3, but postmarketing surveillance has identified cases of persistent dysfunction even after drug cessation 1.

Critical caveat: The absolute magnitude of sexual dysfunction is relatively small (2-4% increase over placebo), and the clinical significance may be limited—one study found the largest effect was only 3.21 points on a 0-100 scale, compared to 1.26 points for each year of aging 3.

Dose Considerations

Both 5mg (for BPH) and 1mg (for male pattern baldness) doses produce similar sexual side effects. The 1mg dose used for alopecia causes approximately 50% PSA suppression at 1 year, similar to the 5mg dose, suggesting comparable systemic effects 3.

Minoxidil and Erectile Dysfunction

No Established Association

Topical minoxidil has no documented association with erectile dysfunction in the 2025 guideline from the Journal of the American Academy of Dermatology 2. The side effect profile for topical minoxidil includes:

  • Scalp irritation, allergic contact dermatitis, photoallergic reactions
  • Hypertrichosis (facial hair growth in ~5% of women using 5% solution)
  • Headaches (<5% of patients)
  • Rare reports of central serous chorioretinopathy

Low-dose oral minoxidil (LDOM) similarly shows no sexual dysfunction in its adverse effect profile 2. The primary concerns with oral minoxidil relate to cardiovascular effects (hypotension, tachycardia) at higher doses, not sexual function.

Mechanistic Distinction

Minoxidil acts as a vasodilator and potassium channel opener, with no direct effects on androgenic pathways 5. While one systematic review suggested minoxidil "could act as a hormone disruptor" in animal models 4, there is no clinical evidence of ED in human studies, and one review specifically noted that topical minoxidil produces only "mild erectile response" when studied as a treatment for ED 5.

Clinical Recommendations

For Patients Considering These Medications:

Finasteride counseling should include:

  • 2-4% absolute risk increase for ED over placebo in the first year
  • Sexual side effects typically decrease with continued use but may persist in rare cases after discontinuation
  • Risk applies to both 1mg (hair loss) and 5mg (BPH) doses
  • Older men with comorbidities and concomitant medications may have difficulty attributing causality 1

Minoxidil counseling:

  • No sexual dysfunction risk
  • Focus on cutaneous side effects (irritation, unwanted hair growth)
  • Cardiovascular monitoring only needed for oral formulations at higher doses

When ED Develops on Finasteride:

  1. Assess temporal relationship: Did ED begin after starting finasteride?
  2. Consider discontinuation trial: Sexual dysfunction may resolve, though persistence has been reported
  3. Evaluate alternative causes: Age, comorbidities, other medications
  4. Document carefully: The independent role of finasteride can be difficult to establish in older patients with multiple risk factors 1

Common pitfall: Attributing all sexual dysfunction to finasteride in older men with BPH, who often have multiple ED risk factors including age, diabetes, cardiovascular disease, and other medications. The natural history of ED in this population makes causality assessment challenging.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.